Obesity Surgery

, Volume 27, Issue 11, pp 3006–3007 | Cite as

Answer to the Letter to the Editor Concerning “Pharmacokinetics in Morbid Obesity: Influence of Two Bariatric Surgery Techniques on Paracetamol and Caffeine Metabolism”

  • Jose Rodríguez-Morató
  • Albert Goday
  • Klaus Langohr
  • Clara Pérez-Mañá
  • Magí Farré
  • Rafael de la Torre
Letter to Editor/LED Reply


Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Grant Information

Not applicable.


  1. 1.
    Goday Arno A, Farré M, Rodríguez-Morató J, et al. Pharmacokinetics in morbid obesity: influence of two bariatric surgery techniques on paracetamol and caffeine metabolism. Obes Surg. 2017;40(6):1–8.Google Scholar
  2. 2.
    Ou-Yang D-S, Huang S-L, Wang W, et al. Phenotypic polymorphism and gender-related differences of CYP1A2 activity in a Chinese population. Br J Clin Pharmacol. 2000;49(2):145–51.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Relling MV, Lin J-s, Ayers GD, et al. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin Pharmacol Ther. 1992;52(6):643–58.CrossRefPubMedGoogle Scholar
  4. 4.
    Fontana RJ, Lown KS, Paine MF, et al. Effects of a chargrilled meat diet on expression of CYP3A, CYP1A, and P-glycoprotein levels in healthy volunteers. Gastroenterol. 1999;117(1):89–98.CrossRefGoogle Scholar
  5. 5.
    Granfors MT, Backman JT, Laitila J, et al. Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2. Clin Pharmacol Ther. 2005;78(4):400–11.CrossRefPubMedGoogle Scholar
  6. 6.
    Tracy TS, Venkataramanan R, Glover DD, et al. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A activity) during pregnancy. Am J Obstet Gynecol. 2005;192(2):633–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Faber MS, Jetter A, Fuhr U. Assessment of CYP1A2 activity in clinical practice: why, how, and when? Basic Clin Pharmacol Toxicol. 2005;97(3):125–34.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  1. 1.Integrative Pharmacology and Systems Neuroscience Research Group, Neurosciences Research ProgramIMIM (Hospital del Mar Medical Research Institute)BarcelonaSpain
  2. 2.Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition (CIBEROBN)Instituto Salud Carlos IIIMadridSpain
  3. 3.Department of Endocrinology and NutritionHospital del MarBarcelonaSpain
  4. 4.Department of MedicineAutonomous University of BarcelonaCerdanyolaSpain
  5. 5.Cardiovascular Risk and Nutrition Research GroupIMIM (Hospital del Mar Medical Research Institute)BarcelonaSpain
  6. 6.Department of Statistics and Operations ResearchPolytechnic University of CataloniaBarcelonaSpain
  7. 7.Department of Pharmacology, Therapeutics and ToxicologyAutonomous University of BarcelonaCerdanyolaSpain
  8. 8.Hospital Universitari Germans Trias i Pujol (IGTP)BadalonaSpain
  9. 9.Department of Experimental and Health SciencesUniversitat Pompeu Fabra (CEXS-UPF)BarcelonaSpain

Personalised recommendations